INFLIXIMAB, MYCOPHENOLATE MOFETIL, Placebo, BEVACIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB
EMERALD-1
Phase 3 small_molecule active
Quick answer
INFLIXIMAB, MYCOPHENOLATE MOFETIL, Placebo, BEVACIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB for Locoregional Hepatocellular Carcinoma (HCC) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Locoregional Hepatocellular Carcinoma (HCC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active